Moulis, Guillaume <br/><br/>
Is the risk of tumour necrosis factor inhibitor-induced lupus or lupus-like syndrome the same with monoclonal antibodies and soluble receptor? A case/non-case study in a nationwide pharmacovigilance database.  [electronic resource] 

 -  Rheumatology (Oxford, England)  Oct 2014 
 - 1864-71 p.  digital 
<br/><br/> Publication Type: Comparative Study; Journal Article 
<br/><br/><label>ISSN: </label>1462-0332 
<br/><br/><label>Standard No.: </label>10.1093/rheumatology/keu214  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adalimumab<br/>Adult<br/>Antibodies, Monoclonal--adverse effects<br/>Antibodies, Monoclonal, Humanized--adverse effects<br/>Case-Control Studies<br/>Databases, Pharmaceutical<br/>Etanercept<br/>Female<br/>Humans<br/>Immunoglobulin G--adverse effects<br/>Infliximab<br/>Lupus Erythematosus, Systemic--chemically induced<br/>Male<br/>Middle Aged<br/>Pharmacovigilance<br/>Receptors, Tumor Necrosis Factor--therapeutic use<br/>Risk Factors<br/>Tumor Necrosis Factor-alpha--antagonists & inhibitors